Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations

NCT01024413 is registered in ClinicalTrials.gov with Chinese Society of Lung Cancer as lead sponsor.

NCT NCT01024413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01024413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations
Lead sponsor
Chinese Society of Lung Cancer
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2009
Completion date
June 30, 2015
Enrollment
256 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thoracic neoplasms